Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study compared the effectiveness and safety of microneedling with PRP versus minoxidil and finasteride topical therapy in adult males with androgenetic alopecia, finding similar hair density improvements in both groups, though microneedling with PRP had a quicker onset of action.

This study observed that patients using a novel topical combination of finasteride and minoxidil for male androgenetic alopecia reported high satisfaction and good tolerance, with few side effects and no need for higher-level care, despite limitations such as retrospective data and no control group.

In this large retrospective study, patients using compounded topical finasteride and minoxidil through a telehealth platform for male androgenetic alopecia reported high satisfaction and low incidence of side effects, with no need for higher care or treatment discontinuation due to adverse reactions.

This study found that users of a German direct-to-consumer teledermatology platform for finasteride reported improvements in hair appearance and self-esteem, though 12% experienced treatment-related adverse events.

This study found that the increasing visits to online prescription platforms for MQ-based finasteride treatment in androgenetic alopecia suggest a significant shift in medical care towards digital health services.

This review of real-world treatment options for AA indicates that current therapies are insufficient, with high dissatisfaction rates, highlighting a need for improved solutions.

In this study, patients using the digitally enabled platform Keeps for male pattern hair loss treatment reported positive health outcomes, with 81% experiencing hair regrowth or ceasing hair loss after six months.

This review discusses the use of topical and intralesional corticosteroids for treating alopecia areata, highlighting their efficacy and safety but noting recurrence and pain as limitations; no new clinical results are reported.

This case report describes a male patient with aromatase deficiency, revealing that a c.628G>A mutation can lead to varied clinical features, such as low bone mass and normal metabolic profiles.

In this study, researchers found that patients with severe alopecia areata often experience reduced health-related quality of life, with significant levels of anxiety and depression, and these mental health impacts may correlate with the severity of their condition.

Female-marketed minoxidil foam is more expensive than male-marketed, but generic and bulk options can reduce this gap.

This index of Harper's Textbook of Pediatric Dermatology, Fourth Edition, provides no clinical results or new findings.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

This study found that individuals with black hair have a significantly higher risk of alopecia areata compared to those with dark brown hair, while lighter hair colors like red or blonde are associated with a lower risk.

This study identified a novel mutation, R430Q in the KRT86 gene, in a Han family with monilethrix, which may contribute to the disease's pathogenic mechanism.

This study found that all four evaluated large language models generated a significant proportion of inappropriate responses when prompted with or without LGBTQIA+ identity terms, with more severe bias observed in prompts mentioning LGBTQIA+ identities.

This study highlights the gap between media claims and limited scientific evidence on the impact of alternative therapies for men's health, emphasizing the need for larger-scale trials for informed patient counseling.

This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.

This study found that patients with alopecia areata face challenges like medical uncertainty and lack of information, highlighting the need for reliable and accessible treatment information that aligns with their preferences.

This study found that treating male pattern androgenetic alopecia with a combination of topical minoxidil and finasteride resulted in better outcomes for hair growth and density compared to using minoxidil alone.

Using both minoxidil and finasteride together on the scalp works better for male hair loss than using either one alone.

The combination of finasteride and minoxidil is as safe and effective as minoxidil alone for improving hair growth in men.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This study found that topical finasteride mixed with minoxidil improved hair appearance and self-esteem in men with androgenetic alopecia, but it was not superior to oral finasteride and had lower treatment adherence.

This study reported that combined oral finasteride and topical 5% minoxidil treatment in men with male-pattern hair loss improved hair growth by initiating anagen in pre-existing but deficient follicles, yet the growth rates remained unchanged and did not normalize hair productivity.

This source highlights topical minoxidil as the first-line treatment for androgenetic alopecia in both genders and finasteride for men, while also identifying dutasteride, low-dose oral minoxidil, and topical finasteride as promising future options.

This review discusses the efficacy of Minoxidil and finasteride for treating androgenetic alopecia and suggests that combined therapy may offer superior results and improved patient adherence despite potential side effects.

This study found that among patients with stage III and IV androgenic alopecia, 83% of those using topical 5% minoxidil with topical 0.1% finasteride showed improved hair density, suggesting it may reduce the need for long-term oral finasteride.

This study found that a combination of topical finasteride 0.25% with minoxidil 5% was more effective than using topical minoxidil 5% alone for treating male pattern androgenic alopecia over a 12-week period.